Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer
Phase 2 (Actuate-1801 Part 3B) trial meets primary endpoint and demonstrates a…
University of Phoenix Announces 2025 UOPX Faculty of the Year Award Recipients
Award honors top UOPX faculty nominated by students and faculty colleaguesPHOENIX--(BUSINESS WIRE)--University…
